97. Ulcerative colitis Clinical trials / Disease details

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03235752 (ClinicalTrials.gov)	February 6, 2018	28/7/2017	Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis	Active Ulcerative Colitis	Drug: TJ301 300mg;Drug: TJ301 600mg;Drug: Placebo	I-Mab Biopharma HongKong Limited	NULL	Recruiting	18 Years	70 Years	All	90	Phase 2	Australia;China;Korea, Republic of;Taiwan
2	EUCTR2016-000205-36-DE (EUCTR)	11/07/2016	14/03/2016	A Clinical Trial to Evaluate Activity, Safety and Tolerability of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD).	A Single-Centre, Exploratory Trial to Assess the Mechanisms of Molecular Activity, Safety and Tolerability of One Dose Level of FE 999301 by Intravenous Infusions in Patients with Active Inflammatory Bowel Disease (IBD) - FUTURE	Inflammatory Bowel Disease (Crohn`s Disease and Ulcerative Colitis) MedDRA version: 19.0;Level: PT;Classification code 10009900;Term: Colitis ulcerative;System Organ Class: 10017947 - Gastrointestinal disorders MedDRA version: 19.0;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Code: FE 999301	University Hospital Schleswig-Holstein (UKSH)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes		Phase 2	Germany